RGLS_OUT_1 [2025-04-28 11:36:04 -0400] 5806 Bytes | 1662 tokens | Cum: 1662 tkns (20.77% of 8k)
==========================================================================

Booyah, my friends! It's already 11:36 AM on Mon Apr 28, 2025, and I've got my eyes locked on Regulus Therapeutics (RGLS), pushing up to $3.52 from $2.76. Are we in for a serious bull run, or is this just hype? I've pulled the data—let's break it down!

--- COMPANY PROFILE ---
Company: Regulus Therapeutics (RGLS)
IPO: 2012-10-04 (12 Years Ago)
Market Cap: $115,925,922
Shares Outstanding: 66,239,999
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

Here’s a list of headlines for Regulus Therapeutics:

Apr-24-25 09:55AM - Should You Buy Regulus (RGLS) After Golden Cross?
Apr-18-25 03:25PM - Is Regulus Therapeutics Inc. (RGLS) the Best Rising Penny Stock to Buy According to Analysts?
Apr-02-25 08:00AM - Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit
Mar-28-25 09:00AM - RNA Biotechs: Current State And Outlook
Mar-27-25 07:00AM - Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Mar-19-25 12:00PM - What Makes Regulus (RGLS) a New Buy Stock
Mar-18-25 04:44AM - Regulus Therapeutics (RGLS): One of the Best Short-Term Stocks to Buy Right Now
Mar-13-25 04:18PM - Regulus: Q4 Earnings Snapshot
Mar-13-25 04:18PM 04:05PM - Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates
Mar-04-25 08:00AM - Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference
Feb-21-25 03:42AM - Regulus Therapeutics Inc. (RGLS): Among the Cheapest Stocks Insiders Are Buying Recently
Feb-04-25 08:00AM - Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Jan-29-25 12:48PM - Regulus Therapeutics Shares Drop 24% Despite Positive ADPKD Trial Data
Jan-29-25 12:48PM 07:00AM - Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)
Nov-26-24 08:00AM - Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences
Nov-07-24 05:13PM - Regulus: Q3 Earnings Snapshot
Nov-07-24 05:13PM 04:05PM - Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates
Oct-29-24 06:01AM - These 2 Strong Buy Penny Stocks Could Rally Over 500%, Say Analysts
Oct-08-24 08:00AM - Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Aug-28-24 08:00AM - Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
Aug-08-24 05:19PM - Regulus: Q2 Earnings Snapshot
Aug-08-24 05:19PM 04:05PM - Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates

Prior AI Reports for RGLS:
1. 2025-04-02 – Score: 45 – Target: 2.9500 – Highs: 2.0100 / 1.9500 / 1.81
mixed-signals-strong-performance-amid-financial-woes
2. 2025-03-27 – Score: 60 – Target: 1.7500 – Highs: 2.0500 / 1.7500 / 1.84
high-volume-sparks-interest-despite-financial-challenges

(Note: Highs = Same day / 2nd day / 3rd day)

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2024-06-25T11:27:06Z - Ball To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Tuesday
B2 - 2024-03-14T17:38:41Z - Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
B3 - 2024-03-14T16:07:00Z - Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
B4 - 2024-03-13T16:09:00Z - Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study
B5 - 2024-03-13T10:18:00Z - How Communities Impact Penny Stocks, 3 Ways
B6 - 2024-03-12T18:57:39Z - Gold Down Over 1%; ClearOne Shares Spike Higher

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Regulus Therapeutics (RGLS).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

RGLS_OUT_3 [2025-04-28 11:36:05 -0400] 698 Bytes | 192 tokens | Cum: 1856 tkns (23.20% of 8k)
==========================================================================

Showing B4 (chunk 1 of 1): B4:
**Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study**Date: Unknown DateSource: Unknown SourceURL: https://www.zacks.com/stock/news/2240223/regulus-rgls-up-71-on-topline-data-from-kidney-disease-studyData from an early-stage study shows that treatment with Regulus' (RGLS) lead drug shows increased biological activity at a higher dose in patients with autosomal dominant polycystic kidney disease.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RGLS_OUT_5 [2025-04-28 11:36:06 -0400] 1009 Bytes | 296 tokens | Cum: 2154 tkns (26.92% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-24T08:39:19Z - Regulus Therapeutics (NASDAQ:RGLS) Stock Price Passes Above 200 Day Moving Average - Time to Sell?...
A2 - 2025-04-21T21:00:07Z - Short Interest in Regulus Therapeutics Inc. (NASDAQ:RGLS) Expands By 30.4%...
A3 - 2025-04-14T06:35:26Z - Regulus Therapeutics (NASDAQ:RGLS) Stock Price Crosses Above 200-Day Moving Average - Time to Sell...
A4 - 2025-04-09T12:11:11Z - Hedge Fund Managers Are Aggressively Buying Biotech Stocks Despite Trump Hinting at Pharma Tariffs...
A5 - 2025-04-09T12:09:44Z - Hedge Fund Managers Are Aggressively Buying Biotech Stocks Despite Trump Hinting at Pharma Tariffs...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

RGLS_OUT_7 [2025-04-28 11:36:07 -0400] 1181 Bytes | 324 tokens | Cum: 2480 tkns (31.00% of 8k)
==========================================================================

Showing A1 (chunk 1 of 7): A1:
**Regulus Therapeutics (NASDAQ:RGLS) Stock Price Passes Above 200 Day Moving Average - Time to Sell?**Date: 2025-04-24Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/instant-alerts/regulus-therapeutics-nasdaqrgls-stock-price-passes-above-200-day-moving-average-time-to-sell-2025-04-22/Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report)'s stock price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.47 and traded as high as $2.11. Regulus Therapeutics shares last traded at $2.01, with a volume of 542,264 shares traded.

A number of research analysts have commented on the stock. Wells Fargo & Company upgraded shares of Regulus Therapeutics from an "equal weight" rating to an "overweight" rating and increased their price target for the company from $3.00 to $

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RGLS_OUT_9 [2025-04-28 11:36:08 -0400] 1181 Bytes | 319 tokens | Cum: 2801 tkns (35.01% of 8k)
==========================================================================

Showing A1 (chunk 2 of 7): 6.00 in a research report on Thursday, March 27th. Canaccord Genuity Group reiterated a "buy" rating and issued a $28.00 target price on shares of Regulus Therapeutics in a research report on Monday, March 17th. Finally, HC Wainwright restated a "buy" rating and set a $10.00 price target on shares of Regulus Therapeutics in a research report on Friday, March 14th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $12.75.

Get Our Latest Report on RGLS

The firm's fifty day moving average price is $1.51 and its 200-day moving average price is $1.47. The stock has a market cap of $133.15 million, a P/E ratio of -1.88 and a beta of 1.03.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last release

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RGLS_OUT_11 [2025-04-28 11:36:08 -0400] 1181 Bytes | 298 tokens | Cum: 3101 tkns (38.76% of 8k)
==========================================================================

Showing A1 (chunk 3 of 7): d its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.20). During the same quarter in the previous year, the firm posted ($0.40) earnings per share. Sell-side analysts predict that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current year.

In other Regulus Therapeutics news, CEO Joseph P. Hagan bought 50,000 shares of the firm's stock in a transaction that occurred on Thursday, January 30th. The stock was bought at an average price of $1.09 per share, for a total transaction of $54,500.00. Following the completion of the acquisition, the chief executive officer now directly owns 260,808 shares in the company, valued at $284,280.72. The trade was a 23.72 % increase in their ownership of the stock. The purchase was disclosed in a do

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RGLS_OUT_13 [2025-04-28 11:36:09 -0400] 1181 Bytes | 288 tokens | Cum: 3391 tkns (42.39% of 8k)
==========================================================================

Showing A1 (chunk 4 of 7): cument filed with the SEC, which is available at this hyperlink. 4.35% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently modified their holdings of RGLS. Octagon Capital Advisors LP lifted its holdings in Regulus Therapeutics by 13.7% in the fourth quarter. Octagon Capital Advisors LP now owns 4,848,802 shares of the biopharmaceutical company's stock worth $7,661,000 after buying an additional 585,101 shares during the period. Millennium Management LLC boosted its position in shares of Regulus Therapeutics by 69.7% during the fourth quarter. Millennium Management LLC now owns 2,192,158 shares of the biopharmaceutical company's stock valued at $3,464,000 after purchasing an additional 900,743 shares in the last quarter. State Street Corp grew its stake in Regulus Therapeutics by 3.5% in the third quarter. State Street Cor

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RGLS_OUT_15 [2025-04-28 11:36:10 -0400] 1181 Bytes | 294 tokens | Cum: 3687 tkns (46.09% of 8k)
==========================================================================

Showing A1 (chunk 5 of 7): p now owns 1,000,998 shares of the biopharmaceutical company's stock worth $1,572,000 after purchasing an additional 33,496 shares during the period. JPMorgan Chase & Co. raised its holdings in Regulus Therapeutics by 141.2% in the fourth quarter. JPMorgan Chase & Co. now owns 190,457 shares of the biopharmaceutical company's stock worth $301,000 after purchasing an additional 111,485 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in Regulus Therapeutics by 20.5% during the fourth quarter. Renaissance Technologies LLC now owns 117,100 shares of the biopharmaceutical company's stock valued at $185,000 after buying an additional 19,900 shares during the period. 92.38% of the stock is owned by hedge funds and other institutional investors.

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of dru

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RGLS_OUT_17 [2025-04-28 11:36:11 -0400] 1181 Bytes | 263 tokens | Cum: 3952 tkns (49.40% of 8k)
==========================================================================

Showing A1 (chunk 6 of 7): gs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider Regulus Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top anal

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RGLS_OUT_19 [2025-04-28 11:36:12 -0400] 556 Bytes | 137 tokens | Cum: 4091 tkns (51.14% of 8k)
==========================================================================

Showing A1 (chunk 7 of 7): ysts are quietly whispering to their clients to buy now before the broader market catches on... and Regulus Therapeutics wasn't on the list.

While Regulus Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RGLS_OUT_21 [2025-04-28 11:36:12 -0400] 1151 Bytes | 311 tokens | Cum: 4404 tkns (55.05% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-27 8-K Item7.01 Regulation FD Disclosure.

Furnished as Exhibit 99.1 to this report is a presentation of Regulus Therapeutics Inc. (the Company), relating to topline results from the fourth cohort of patients in the Companys Phase 1b multiple-ascending dose (MAD) study of farabursen (R...

S2 - 2025-03-27 8-K Item7.01 Regulation FD Disclosure.

Furnished as Exhibit 99.1 to this report is a presentation of Regulus Therapeutics Inc. (the Company), relating to topline results from the fourth cohort of patients in the Companys Phase 1b multiple-ascending dose (MAD) study of farabursen (R...

S3 - 2025-03-27 8-K Item7.01 Regulation FD Disclosure.

Furnished as Exhibit 99.1 to this report is a presentation of Regulus Therapeutics Inc. (the Company), relating to topline results from the fourth cohort of patients in the Companys Phase 1b multiple-ascending dose (MAD) study of farabursen (R...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

RGLS_OUT_23 [2025-04-28 11:36:13 -0400] 1151 Bytes | 288 tokens | Cum: 4694 tkns (58.67% of 8k)
==========================================================================

Showing S1 (chunk 1 of 1): S1:
Item7.01 Regulation FD Disclosure.

Furnished as Exhibit 99.1 to this report is a presentation of Regulus Therapeutics Inc. (the Company), relating to topline results from the fourth cohort of patients in the Companys Phase 1b multiple-ascending dose (MAD) study of farabursen (RGLS8429) for the treatment of autosomal dominant polycystic kidney disease (ADPKD).

The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing....

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RGLS_OUT_25 [2025-04-28 11:36:22 -0400] 5902 Bytes | 1577 tokens | Cum: 6273 tkns (78.41% of 8k)
==========================================================================

This is our set of metrics for Regulus Therapeutics.
Please analyze the numbers.

+-------------------+-----------------------+-------------------------+----------------------+
| Volume: 1,608,929 | Perf Month: 128.00% | Option/Short: Yes / Yes | Sales Y/Y TTM: - |
+-------------------+-----------------------+-------------------------+----------------------+
| Avg Volume: 1.24M | Perf Quarter: 187.39% | Short Float: 3.97% | ROE: -95.00% |
+-------------------+-----------------------+-------------------------+----------------------+
| Rel Volume: 4.09 | Index: RUT | Short Ratio: 1.71 | ROI: -60.45% |
+-------------------+-----------------------+-------------------------+----------------------+
| RSI (14): 86.40 | Market Cap: 226.55M | Short Interest: 2.11M | Sales Surprise: - |
+-------------------+-----------------------+-------------------------+----------------------+
| ATR (14): 0.24 | Shs Outstand: 65.50M | Beta: 0.92 | EPS Surprise: 4.76% |
+-------------------+-----------------------+-------------------------+----------------------+
| SMA20: 66.52% | Shs Float: 53.18M | Sales Q/Q: - | P/E: - |
+-------------------+-----------------------+-------------------------+----------------------+
| SMA50: 109.21% | Inst Own: 67.96% | Sales past 5Y: -10.71% | Earnings: Mar 13 AMC |
+-------------------+-----------------------+-------------------------+----------------------+
| SMA200: 120.39% | Insider Own: 19.71% | Employees: 34 | |
+-------------------+-----------------------+-------------------------+----------------------+
| Perf Week: 70.15% | Insider Trans: -1.33% | Debt/Eq: 0.01 | |
+-------------------+-----------------------+-------------------------+----------------------+

The next section covers any insider trading by Regulus Therapeutics officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -46358000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 3.51
Average Volume: 1090431.9
30-Day High: 3.51
30-Day Low: 1.6

[Detailed Financials: TTM 2024]
- Total Assets: $84,181,000.00
- Total Liabilities: $7,773,000.00
- Total Equity: $76,408,000.00
- Current Assets: $82,345,000.00
- Current Liabilities: $7,499,000.00

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: $-46,358,000.00
- Gross Profit: N/A
- Operating Income: $-50,040,000.00
- Earnings Per Share (EPS): -0.82

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $14,761,000.00

[Detailed Financials: FY 2024]
- Total Assets: $84,181,000.00
- Total Liabilities: $7,773,000.00
- Total Equity: $76,408,000.00
- Current Assets: $82,345,000.00
- Current Liabilities: $7,499,000.00

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: $-46,358,000.00
- Gross Profit: N/A
- Operating Income: $-50,040,000.00
- Earnings Per Share (EPS): -0.82

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $14,761,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Regulus Therapeutics (RGLS).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Regulus Therapeutics.

2) MARKET_SCORE[]
This conversation was initiated because RGLS is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for RGLS.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, RGLS could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect RGLS to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Regulus Therapeutics.

11) ETHICAL_RATING[]
Rate Regulus Therapeutics’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Regulus Therapeutics.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

RGLS_IN_27 [2025-04-28 11:36:22 -0400] 126 Bytes | 29 tokens | Cum: 6510 tkns (81.38% of 8k)
==========================================================================

====================================
[2025-04-28 11:36:22] # Analysis Completed
Elapsed Time: 19.13 seconds